We have had our interesting discussions about the different Omega 3 supplements. I think this adds some extra value.
chatGPT:
Tidy transcript
Title: “Concerning Omega-3 Brain Study” — Dr Brad Stanfield
In 2024, I made a video called Your Brain on Omega-3, where I said that omega-3 plus B vitamins was a good option for brain health. But last week, a new study appeared that found the opposite.
In that study, older adults who took omega-3 supplements declined faster on every cognitive test the researchers measured. The mechanism proposed by the authors was not subtle: they argued that omega-3 in commercial fish oil may go rancid and damage brain mitochondria.
So I went back and reread my own 2024 script, reread every paper I cited, and then examined this new study from start to finish. Here is where I landed: the signal in the new study is real, but the study did not measure two things that may decide whether omega-3 helps or harms the brain. Once those two factors are put back into the picture, the answer changes.
The new paper was published in the Journal of Prevention of Alzheimer’s Disease. It used the ADNI database, one of the best longitudinal cohort datasets in the world. The researchers identified 273 people who said they were taking omega-3 supplements and matched each of them with two similar non-users. They matched for age, sex, baseline memory status, and genetic Alzheimer’s risk. Both groups were then followed for a median of five years.
Across every cognitive test, the omega-3 group declined faster.
A possible objection is reverse causality. People often start taking a supplement because they have noticed something is wrong. Perhaps their memory has slipped, or a partner has noticed a change. They start taking omega-3, but the decline that was already underway continues, and the supplement gets blamed.
The authors tried to address this. They looked at omega-3 users before they began supplementation and compared their cognitive scores and brain scans with people who never used omega-3. Before supplementation, the two groups appeared to be tracking similarly. That is an important check, and the authors deserve credit for doing it.
However, the authors also concede a limitation: the study may not detect the subtle early changes that prompt someone to buy a supplement in the first place. ADNI participants are often already concerned about memory. So even though the authors tried to control for reverse causality, the concern remains.
The imaging data are particularly interesting. The researchers looked at amyloid, tau, grey-matter atrophy, and FDG-PET, which measures brain glucose metabolism. Three of the four biomarkers were flat: there was no association with amyloid, no association with tau, and no association with grey-matter volume. The only biomarker that moved was glucose metabolism.
The brain runs heavily on glucose. FDG-PET showed that the omega-3 group’s brains used less glucose over time, a pattern linked to cognitive decline. So the question becomes: why would omega-3 supplement users show declining brain glucose metabolism?
DHA is the omega-3 fatty acid most enriched in the brain. It is also chemically vulnerable because oxygen can attack weak points in the molecule. In direct lab measurements, DHA oxidises around five times faster than linoleic acid, the main fat in seed oils, and much faster than monounsaturated fats in extra-virgin olive oil. Grey matter is also rich in DHA.
That is the mechanism proposed by the new study’s authors: if DHA fats are going rancid inside the brain, they could impair mitochondrial function, which could show up as reduced brain energy use on scans.
The story is biologically coherent, but it rests on a major assumption. It requires that omega-3 supplements were already oxidised before entering the body, or that the body was not handling them well, or both.
This leads to a key paper by Ben Albert from the University of Auckland. Researchers bought 32 fish-oil supplements from a New Zealand pharmacy and tested them. Only three contained what the label claimed, and 83% exceeded oxidation limits. The industry pushed back on the methods, and follow-up work found fewer oxidised products, so it is an overclaim to say all fish oil is rancid. But supplement quality is clearly variable.
The problem is that the ADNI study did not measure oxidation. It did not record supplement brand, whether the omega-3 was in ethyl ester or triglyceride form, or whether bottles had been stored badly for long periods. Exposure was simply self-reported omega-3 use: yes or no. So we do not know whether supplement quality influenced the findings.
But supplement quality is only half the story.
The other half comes from the VITACOG trial. VITACOG was a randomised clinical trial in older adults with mild cognitive impairment. Participants received high-dose B vitamins — folic acid, B6, and B12 — or placebo for two years. The primary outcome was brain shrinkage on MRI.
The key finding was that whether B vitamins worked depended on omega-3 status. If omega-3 levels in the blood were low, B vitamins did not appear to help brain health. But if omega-3 levels were in a healthy range, B vitamins had an effect on MRI brain outcomes. A later analysis replicated the idea that omega-3 and B vitamins interact.
Putting the VITACOG work together, omega-3 and B vitamins may not be independent. The work suggests they function as a pair: healthy omega-3 status and adequate B-vitamin status, reflected partly by lower homocysteine, may be needed for positive brain effects.
The ADNI study did not measure homocysteine or B-vitamin levels. That means some omega-3 users may have been B-vitamin deficient or had elevated homocysteine. If so, omega-3 in a B-vitamin-deficient person might look very different from omega-3 in someone with adequate B-vitamin status.
So the new study tested omega-3 as though it were a standalone variable. The VITACOG work suggests it may not be.
My personal view has not changed. I still take omega-3 at around 1 gram per day for potential cognitive effects and for cardiovascular health, drawing on evidence from the VITAL trial and a Mayo Clinic meta-analysis. I use a brand that is third-party tested, eat a good diet, and take a methylated B-vitamin complex plus TMG to help lower homocysteine.
But just because I take a supplement does not mean you should. Discuss it with your doctor.
Omega-3 supplements are often paired with antioxidants to protect against oxidation. A new antioxidant study has recently been published showing possible benefits for muscle health, but only in certain populations. That is the topic of the next video.
Summary
The video discusses a new 2026 observational ADNI study reporting that older adults who self-reported omega-3 supplement use had faster cognitive decline over about five years. The finding was not linked to amyloid, tau, or grey-matter loss, but was associated with reduced brain glucose metabolism on FDG-PET, suggesting a possible energy-metabolism link. The paper itself reports an association, not proof of causation. (ScienceDirect)
Stanfield’s central argument is that the study is concerning but incomplete. He accepts that the cognitive signal is real, but says two missing variables matter: the oxidation quality of the fish-oil supplements and the participants’ B-vitamin/homocysteine status.
He argues that rancid or oxidised fish oil is biologically plausible as a harmful exposure because DHA is highly oxidation-prone, and oxidised lipids could plausibly impair mitochondrial function. He cites the New Zealand fish-oil testing study, in which many tested products failed label or oxidation standards, although subsequent industry-linked and other critiques challenged the generalisability of that finding. (PubMed)
He then argues that omega-3 may need to be interpreted alongside B-vitamin status. The VITACOG work found that B-vitamin effects on brain atrophy/cognition appeared stronger when omega-3 status was adequate, and weaker or absent when omega-3 status was low. (PubMed)
His practical conclusion is cautious continuity: he personally continues taking about 1 g/day omega-3, uses third-party-tested products, supports homocysteine control with B vitamins/TMG, and advises viewers to consult their doctor rather than copying his regimen.
Critique
1. The video gives the new ADNI result appropriate weight, but may still understate confounding.
Stanfield correctly notes reverse causality: people may start omega-3 because they or their family already notice cognitive decline. The ADNI authors attempted to address this by looking at pre-supplement trajectories, but observational supplement-use studies are still vulnerable to confounding by health anxiety, medical history, socioeconomic status, diet, supplement stacking, medication use, and clinician advice. The new study is hypothesis-generating, not a basis for concluding omega-3 causes cognitive decline.
2. The oxidation hypothesis is plausible but not demonstrated in the ADNI study.
The proposed mechanism — oxidised DHA impairing mitochondrial function and brain glucose metabolism — is coherent. However, the ADNI study did not measure supplement oxidation, brand, dose, storage, chemical form, or blood omega-3 status. So the oxidation explanation is a plausible rescue hypothesis, not evidence that oxidation caused the observed decline. Stanfield does say this, which is a strength of the video.
3. The VITACOG argument is interesting, but it is not a complete rebuttal.
The VITACOG data support an interaction between omega-3 status and B-vitamin/homocysteine biology. However, that does not automatically mean omega-3 supplementation is beneficial when B-vitamin status is good, nor that poor B-vitamin status explains the ADNI harm signal. VITACOG mainly tested B-vitamin therapy stratified by omega-3 status, whereas the ADNI study examined omega-3 supplement users versus non-users. These are related but not the same causal question.
4. The video blurs “omega-3 status” and “omega-3 supplementation.”
This is a key distinction. Higher blood omega-3 levels from fish intake, overall diet quality, or good metabolic health may not be equivalent to taking commercial fish-oil capsules. The ADNI signal concerns supplement use; the VITACOG interaction concerns blood omega-3 status. Those should not be treated as interchangeable.
5. The cardiovascular justification is only partly relevant to the brain-health claim.
Stanfield says he continues omega-3 partly for cardiovascular reasons, citing VITAL and meta-analytic work. That may be reasonable for his personal risk calculus, but cardiovascular outcome evidence does not directly settle whether omega-3 supplementation helps or harms cognition in older adults.
6. The commercial context should be noted.
The video includes promotion of Stanfield’s own supplement products and mentions his own B-vitamin/TMG regimen. That does not invalidate the analysis, but it creates a potential conflict of interest. A viewer should separate the scientific argument from the product framing.
Overall assessment:
The video is a fair and useful response to a worrying observational study. Its strongest point is that “omega-3 supplement use” is too crude an exposure variable: dose, oxidation, formulation, storage, diet, blood omega-3 status, B-vitamin status, and homocysteine could all matter. Its weakest point is that the proposed explanations — rancid fish oil and inadequate B-vitamin status — are plausible but unproven in the ADNI dataset. The best conclusion is not “omega-3 is harmful” or “omega-3 is vindicated,” but: future trials need to measure supplement quality, omega-3 index, homocysteine, B-vitamin status, dose, formulation, and cognitive/imaging outcomes together.
